104 related articles for article (PubMed ID: 3109935)
1. Blood clonal B cell excess at diagnosis in multiple myeloma: relation to prognosis.
Osterborg A; Nilsson B; Björkholm M; Holm G; Johansson B; Lindemalm C; Petterson D; Ahre A; Mellstedt H
Eur J Haematol; 1987 Feb; 38(2):173-8. PubMed ID: 3109935
[TBL] [Abstract][Full Text] [Related]
2. Blood clonal B cell excess (CBE) at diagnosis in patients with non-Hodgkin lymphoma (NHL). Relation to clinical stage, histopathology and response to treatment.
Lindemalm C; Mellstedt H; Nilsson B; Biberfeld P; Björkholm M; Christensson B; Holm G; Johansson B
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):749-53. PubMed ID: 3115783
[TBL] [Abstract][Full Text] [Related]
3. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation.
Isaksson E; Björkholm M; Holm G; Johansson B; Nilsson B; Mellstedt H; Osterborg A
Br J Haematol; 1996 Jan; 92(1):71-6. PubMed ID: 8562414
[TBL] [Abstract][Full Text] [Related]
4. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
5. Monitoring myeloma: light chain isotype suppression. A new parameter.
Wearne A; Joshua DE; Kronenberg H
Aust N Z J Med; 1985 Oct; 15(5):629-33. PubMed ID: 3937514
[TBL] [Abstract][Full Text] [Related]
6. Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase.
Wearne A; Joshua DE; Kronenberg H
Br J Haematol; 1984 Nov; 58(3):483-9. PubMed ID: 6437432
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
8. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
[TBL] [Abstract][Full Text] [Related]
9. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.
Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L
Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of immunoglobulin light chain isotype in B lymphocytes from patients with monoclonal gammopathies: isotypic discordance and clonal B-cell excess.
Oritani K; Katagiri S; Tominaga N; Iida M; Amano T; Karasuno T; Matsumura I; Mitsui H; Kanayama Y; Yonezawa T
Br J Haematol; 1990 May; 75(1):10-5. PubMed ID: 2115808
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulation and prognosis in myeloma.
Joshua DE; Wearne A; Kronenberg H
Lancet; 1987 Jan; 1(8527):251-3. PubMed ID: 2880070
[TBL] [Abstract][Full Text] [Related]
12. Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma.
Nelson M; Brown RD; Gibson J; Joshua DE
Br J Haematol; 1992 Jun; 81(2):223-30. PubMed ID: 1643019
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin isotypes on monoclonal blood lymphocytes in human plasma cell myeloma.
Pettersson D; Mellstedt H; Holm G
J Clin Lab Immunol; 1980 Mar; 3(2):93-8. PubMed ID: 6782249
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
15. Monitoring circulating B cells in patients with multiple myeloma at diagnosis or in plateau phase: how prevalent is light chain isotype suppression?
King MA; Radicchi MA
Br J Haematol; 1992 Jun; 81(2):218-22. PubMed ID: 1379466
[TBL] [Abstract][Full Text] [Related]
16. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
17. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
18. IgA-lambda/IgG-kappa biclonal myeloma in which two clones proliferated in individual sites.
Ando K; Yaguchi M; Okabe S; Miyazawa K; Ohyashiki K
Intern Med; 2000 Feb; 39(2):170-5. PubMed ID: 10732840
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood B lymphocytes in multiple myeloma.
Tienhaara A; Pelliniemi TT
Acta Haematol; 1994; 91(2):57-61. PubMed ID: 7517607
[TBL] [Abstract][Full Text] [Related]
20. Circulating monotypic B-cells in multiple myeloma: association with lambda paraproteins.
Bagg A; Becker P; Bezwoda W; van Rensburg L; Mendelow B
Br J Haematol; 1989 Jun; 72(2):167-72. PubMed ID: 2503024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
